Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

Back to Search
Print
Bookmark Trial

NCT00314964

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Phoenix, Arizona, 85015, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hot Flashes
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40-70 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels >40mlU/ml and estradiol < than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels > 40 mlU/ml and estradiol < than = 25 pg/mL

- Women reporting at least 50 moderate to severe vasomotor symptoms per week, recorded for seven consecutive days

- Aged 40 to 70 years

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- No estrogen monotherapy or estrogen/progesterone containing drug products within
applicable wash out period prior to screening


- Use of SERMs, clonidine within 4 weeks of screening


- Use of CNS active medication within 1 week of screening


- Use of medications (SSRI; SNRI), herbal or dietary supplements, including black
cohosh, soy, phytoestrogens or over the counter agent known to possibly be effective
for the treatment of vasomotor symptoms, within 4 weeks of screening


- Participation in clinical trial within 30 days


- Significant medical or psychiatric illness within past 12 months

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Hot FlashesStudy Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
NCT00314964
  1. Phoenix, Arizona
  2. Phoenix, Arizona
  3. Tucson, Arizona
  4. Tucson, Arizona
  5. Jonesboro, Arkansas
  6. Greenbrae, California
  7. San Diego, California
  8. San Diego, California
  9. New London, Connecticut
  10. Leesburg, Florida
  11. Longwood, Florida
  12. Tampa, Florida
  13. Tampa, Florida
  14. West Palm Beach, Florida
  15. Alanta, Georgia
  16. Alpharetta, Georgia
  17. Atlanta, Georgia
  18. Decatur, Georgia
  19. Stockbridge, Georgia
  20. Chicago, Illinois
  21. Indianapolis, Indiana
  22. Indianapolis, Indiana
  23. Indianapolis, Indiana
  24. Baltimore, Maryland
  25. North Dartmouth, Massachusetts
  26. Chaska, Minnesota
  27. Waconia, Minnesota
  28. Olive Branch, Mississippi
  29. Springfeild, Missouri
  30. Springfeild, Missouri
  31. Lincoln, Nebraska
  32. Omaha, Nebraska
  33. Lebanon, New Hampshire
  34. Lawrenceville, New Jersey
  35. New Brunswick, New Jersey
  36. New Bern, North Carolina
  37. Raleigh, North Carolina
  38. Winston-Salem, North Carolina
  39. Cincinnati, Ohio
  40. Cleveland, Ohio
  41. Columbus, Ohio
  42. Sellersville, Pennsylvania
  43. Columbia, South Carolina
  44. Austin, Texas
  45. San Antonio, Texas
  46. San Antonio, Texas
  47. San Antonio, Texas
  48. Salt Lake City, Utah
  49. Salt Lake City, Utah
  50. Arlington, Virginia
  51. Richmond, Virginia
  52. Richmond, Virginia
  53. Richmond, Virginia
  54. Virginia Beach, Virginia
  55. Seattle, Washington
  56. Spokane, Washington
  57. Randwick, New South Wales
  58. Dulwich, South Australia
  59. Clayton, Victoria
  60. Subiaco, Western Australia
  61. Winnipeg, Manitoba
  62. Burlington, Ontario
  63. Toronto, Ontario
  64. Montreal, Quebec
  65. Québec, Quebec
  66. Montpellier, Cedex 5
  67. Evry,
  68. Nantes,
  69. Paris,
  70. Central, Port Elizabeth, Eastern Cape
  71. Johannesburg, Gauteng
  72. Midrand, Gauteng
  73. Radiokop, Gauteng
  74. Dundee, Kwa-Zulu Natal
  75. Westville, Kwa-Zulu Natal
  76. Parow, Western Cape
  77. Oviedo, Asturias
  78. Gava, Barcelona
  79. Madrid,
  80. Valencia,
Female
40 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause
Official Title  ICMJE A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study Evaluating PD-0299685 for Treatment of Vasomotor Symptoms Associated With Menopause
Brief Summary The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Hot Flashes
Intervention  ICMJE Drug: PD-0299685
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 14, 2011)		527
Original Enrollment  ICMJE
 (submitted: April 13, 2006)		490
Actual Study Completion Date  ICMJE July 2007
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels >40mlU/ml and estradiol < than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels > 40 mlU/ml and estradiol < than = 25 pg/mL
  • Women reporting at least 50 moderate to severe vasomotor symptoms per week, recorded for seven consecutive days
  • Aged 40 to 70 years

Exclusion Criteria:

  • No estrogen monotherapy or estrogen/progesterone containing drug products within applicable wash out period prior to screening
  • Use of SERMs, clonidine within 4 weeks of screening
  • Use of CNS active medication within 1 week of screening
  • Use of medications (SSRI; SNRI), herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agent known to possibly be effective for the treatment of vasomotor symptoms, within 4 weeks of screening
  • Participation in clinical trial within 30 days
  • Significant medical or psychiatric illness within past 12 months
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Ages  ICMJE 40 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Canada,   France,   South Africa,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00314964
Other Study ID Numbers  ICMJE A4291023
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP